Coronary Artery Disease: Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 2, 2014, Pages 86-92

  Teramoto, Tamio ^a   Sasaki, Jun ^a   Ishibashi, Shun ^a   Birou, Sadatoshi ^a   Daida, Hiroyuki ^a   Dohi, Seitaro ^a   Egusa, Genshi ^a   Hiro, Takafumi ^a   Hirobe, Kazuhiko ^a   Iida, Mami ^a   Kihara, Shinji ^a   Kinoshita, Makoto ^a   Maruyama, Chizuko ^a   Ohta, Takao ^a   Okamura, Tomonori ^a   Yamashita, Shizuya ^a   Yokode, Masayuki ^a   Yokote, Koutaro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MEGADOSE; HUMAN; MEDICAL SOCIETY; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RESEARCH REPORT; SOCIETIES, MEDICAL; TIME FACTORS;

EID: 84894636684     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.19158     Document Type: Article

References (62)

1. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y: for the MEGA Study Group: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet, 2006; 368: 1155-1163.
2. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H; J-LIT Study Group: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia: primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J, 2002; 66: 1087-1095.
3. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H; J-LIT Study Group. Japan Lipid Intervention Trial: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J, 2002; 66: 1096-1100.
4. Matsuzaki M, Yokoyama M, Saito Y, et al; JELIS Investigators: Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J, 2009; 73: 1283-1290.
5. Japanese Coronary Artery Disease (JCAD) Study Investigators: Current status of the background of patients with coronary artery disease in Japan. Circ J, 2006; 70: 1256-1262.
6. Furukawa Y, Taniguchi R, Ehara N, Ozasa N, Haruna Y, Saito N, Doi T, Hoshino K, Shizuta S, Morimoto T, Imai Y, Teramukai S, Fukushima M, Kita T, Kimura T; CREDO-Kyoto Investigators: Better survival with statin administration after revascularization therapy in Japanese patients with coronary artery disease: perspectives from the CREDO-Kyoto registry. Circ J, 2008; 72: 1937-1945.
7. Sato H, Kinjo K, Ito H, Hirayama A, Nanto S, Fukunami M, Nishino M, Lim YJ, Kijima Y, Koretsune Y, Nakatani D, Mizuno H, Shimizu M, Hori M; Osaka Acute Coronary Insufficiency Study (OACIS)-LIPID Study Investigators: Effect of early use of low dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: The OACIS-LIPID Study. Cir J, 2008; 72: 17-22.
8. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 2001; 285: 1711-1718.
9. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350: 1495-1504.
10. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, Kayikçioglu M, Arntz HR, den Hartog FR, Veeger NJ, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ: Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta170 analysis of randomized controlled trials. JAMA, 2006; 295: 2046-2056.
11. Hulten E, Jackson JL, Douglas K, George S, Villines TC: The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med, 2006; 166: 1814-1821.
12. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H: Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation, 2004; 110: 1061-1068.
13. Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Yanagisawa N, Tamura H, Kojima T, Yokoyama K, Kurata T, Daida H: Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study. Atherosclerosis, 2010; 210: 497-502.
14. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M; JAPAN-ACS Investigators: Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] study). J Am Coll Cardiol, 2009; 54: 293-302.
15. Goldenberg I, Jonas M, Tenenbaum A, Boyko V, Matetzky S, Shotan A, Behar S, Reicher-Reiss H; Bezafibrate Infarction Prevention Study Group: Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med, 2003; 163: 2301-2305.
16. Critchley JA, Capewell S: Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA, 2003; 290: 86-97.
17. van Domburg RT, Meeter K, van Berkel DF, Veldkamp RF, van Herwerden LA, Bogers AJ: Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol, 2000; 36: 878-883.
18. Rea TD, Heckbert SR, Kaplan RC, et al: Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med, 2002; 137: 494-500.
19. Wilson K, Gibson N, Willan A, Cook D: Effects of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med, 2000; 160: 939-944.
20. REACH Registry Investigators: Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA, 2010; 304: 1350-1357.
21. Kinjo K, Sato H, Sakata Y, Nakatani D, Mizuno H, Shimizu M, Sasaki T, Kijima Y, Nishino M, Uematsu M, Tanouchi J, Nanto S, Otsu K, Hori M; Osaka Acute Coronary Insufficiency Study (OACIS) Group: Impact of smoking status on long-term mortality in patients with acute myocardial infarction. Circ J, 2005; 69: 7-12.
22. Baba S, Iso H, Mannami T, Sasaki S, Okada K, Konishi M; Shoichiro Tsugane; JPHC Study Group: Cigarette smoking and risk of coronary heart disease incidence among middle-aged Japanese men and women: the JPHC Study Cohort I. Eur J Cardiovasc Prev Rehabil, 2006; 13: 207-213.
23. Frey P, Waters DD, DeMicco DA, Breazna A, Samuels L, Pipe A, Wun CC, Benowitz NL: Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials). Am J Cardiol, 2011; 107: 145-150.
24. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ: The metabolic syndrome and cardiovascular risk: A systematic review and meta-analysis. J Am Coll Cardiol, 2010; 56: 1113-1132.
25. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators: Reduction of lowdensity lipoprotein cholesterol in patients with coronary heart disease and metabolic syn-drome: analysis of the Treating to New Targets study. Lancet, 2006; 368: 919-928.
26. Kasai T, Miyauchi K, Kurata T, Okazaki S, Kajimoto K, Kubota N, Daida H: Impact of metabolic syndrome among patients with and without diabetes mellitus on long-term outcomes after percutaneous coronary intervention. Hypertens Res, 2008; 31: 235-241.
27. Kasai T, Miyauchi K, Kajimoto K, Kubota N, Kurata T, Amano A, Daida H: The impact of pravastatin therapy on long-term outcomes in patients with metabolic syndrome undergoing complete coronary revascularization. Circ J, 2009; 73: 2104-2109.
28. Levantesi G, Macchia A, Marfisi R, Franzosi MG, Maggioni AP, Nicolosi GL, Schweiger C, Tavazzi L, Tognoni G, Valagussa F, Marchioli R; GISSIP revenzione Investigators: Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol, 2005; 46: 277-283.
29. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM: Diabetes and mortality following acute coronary syndromes. JAMA, 2007; 298: 765-775.
30. Costa J, Borges M, David C, Vaz Carneiro A: Efficacy of lipid lowering drug treatment for diabetic and nondiabetic patients: meta-analysis of randomised controlled trials. BMJ, 2006; 332: 1115-1124.
31. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a metaanalysis. Lancet, 2008; 371: 117-125.
32. Takara A, Ogawa H, Endoh Y, Mori F, Yamaguchi J, Takagi A, Koyanagi R, Shiga T, Kasanuki H, Hagiwara N: Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization. Cardiovascular Diabetology, 2010; 366: 9: 1-7.
33. Kohsaka S, Kimura T, Goto M, Lee VV, Elayda M, Furukawa Y, Fukushima M, Komeda M, Sakata R, Willerson JT, Wilson JM, Kita T: Difference in patient profiles and outcomes in Japanese versus American patients undergoing coronary revascularization (Collaborative study by CREDO-Kyoto and the Texas Heart Institute Research database). Am J Cardiol, 2010; 105: 1698-1704.
34. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278.
35. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D; Treating to New Targets Investigators: Effects of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care, 2006; 29: 1220-1226.
36. Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, Shreevatsa A, Lavoie AJ, Wolski K, Schoenhagen P, Nissen SE: Clinical predictors of plaque progression despite very low levels of low-density lipoprotein choles-terol. J Am Coll Cardiol, 2010; 55: 2736-2742.
37. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M; JAPANACS Investigators: Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome-serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). Circ J, 2010; 74: 1165-1174.
38. Arai H, Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M; JAPAN-ACS Investigators: More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome-sub-analysis of JAPAN-ACS study. J Athroscler Thromb, 2010; 17: 1096-1107.
39. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA, 2006; 295: 180-189.
40. Scandinavian Simvastatin Survival Study group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389.
41. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998; 339: 1349-1357.
42. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moyé LA, Piller LB, Rutherford J, Simpson LM, Braunwald E: Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. Circulation, 1999; 99: 216-223.
43. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med, 1992; 326: 381-386.
44. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S; REACH Registry Investigators: Oneyear cardiovascular event rates in outpatients with atherothrombosis. JAMA, 2007; 297: 1197-1206.
45. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D; Cardiovascular Health Study Collaborative Research Group: Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Artherioscle Thromb Vasc Biol, 1999; 19: 538-545.
46. McDermott MM, Mandapat AL, Moates A, Albay M, Chiou E, Celic L, Greenland P: Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arc Intern Med, 2003; 163: 2157-2162.
47. Golomb BA, Dang TT, Criqui MH: Peripheral arterialdisease: morbidity and mortality implications. Circulation, 2006; 114: 688-699.
48. Sprengers RW, Janssen KJ, Moll FL, Verhaar MC, van der Graaf Y; SMART Study Group; SMART Study Group: Prediction rule for cardiovascular events and mortality in peripheral arterial disease patients: data from the prospective Second Manifestations of Arterial disease (SMART) cohort study. J Vasc Surg, 2009; 50: 1369-1377.
49. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC: Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev, CD000123, 2007.
50. Schanzer A, Hevelone N, Owens CD, Beckman JA, Belkin M, Conte MS: Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg, 2008; 47: 774-781.
51. Heart Protection Study Collaborative Group: Randomized trial of the effects of cholesterol lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg, 2007; 45: 645-654.
52. Feringa HH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, Galal W, Vidakovic RV, Tangelder MJ, Poldermans D: Cardioprotective medication is associated with improved survival in patients with peripheralarterial disease. J Am Coll Cardiol, 2006; 47: 1182-1187.
53. Hoeks SE, Scholte Op Reimer WJ, Schouten O, Lenzen MJ, van Urk H, Poldermans D: Statin use in the elderly: results from a peripheral vascular survey in The Netherlands. J Vasc Surg, 2008; 48: 891-896.
54. Daskalopoulou SS, Daskalopoulos ME, Mikhailidis DP, Liapis CD: Lipid management and peripheral arterial disease. Curr Drug Targets, 2007; 8: 561-570.
55. Hussein AA, Uno K, Wolski K, Kapadia S, Schoenhagen P, Tuzcu EM, Nissen SE, Nicholls SJ: Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol, 2011; 57: 1220-1225.
56. Kasai T, Miyauchi K, Kajimoto K, Kubota N, Dohi T, Tsuruta R, Ogita M, Yokoyama T, Amano A, Daida H.L: Prognostic significance of glomerular filtration rate estimated by the Japanese equation among patients who underwent complete coronary revascularization. Hypertens Res, 2011; 34: 378-383.
57. Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Tamura H, Kojima T, Yokoyama K, Kurata T, Daida H: Long-term impact of mild chronic kidney disease in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Nephrol Dial Transplant, 2011; 26: 2906-2911.
58. Furukawa Y, Ehara N, Taniguchi R, Haruna Y, Ozasa N, Saito N, Doi T, Hoshino K, Tamura T, Shizuta S, Abe M, Toma M, Morimoto T, Teramukai S, Fukushima M, Kita T, Kimura T; CREDO-Kyoto Investigators: Coronary risk factor profile and prognostic factors for young Japanese patients undergoing coronary revascularization. Circ J, 2009; 73: 1459-1465.
59. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J: Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis, 2007; 49: 373-382.
60. Tonelli M, Moyé L, Sacks FM, Kiberd B, Curhan G; Cholesterol and Recurrent Events (CARE) trial investigators: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med, 2003; 138: 98-104.
61. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators: Focused atrovasttin therapy in managed-care patients with coro-nary heart disease and CKD. Am J Kidney Dis, 2009; 53: 741-750.
62. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators: Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol, 2008; 51: 1448-1454